KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Liabilities and Shareholders Equity (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $465.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 35.5% year-over-year to $465.9 million, compared with a TTM value of $1.5 billion through Dec 2025, up 8.51%, and an annual FY2025 reading of $465.9 million, up 35.5% over the prior year.
  • Liabilities and Shareholders Equity was $465.9 million for Q4 2025 at Esperion Therapeutics, up from $364.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $465.9 million in Q4 2025 and bottomed at $205.8 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $308.6 million, with a median of $313.5 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity plummeted 35.02% in 2022, then skyrocketed 67.07% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $381.6 million in 2021, then tumbled by 35.02% to $247.9 million in 2022, then fell by 17.0% to $205.8 million in 2023, then soared by 67.07% to $343.8 million in 2024, then skyrocketed by 35.5% to $465.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ESPR at $465.9 million in Q4 2025, $364.0 million in Q3 2025, and $347.1 million in Q2 2025.